XML 50 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Share Capital and Other Equity Instruments (Tables)
3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Schedule of Stock Options
    Number of Shares     Weighted Average Exercise Price (USD)     Weighted Average Grant Date Fair Value (USD)     Weighted Average Remaining Contractual Term (years)     Aggregate Intrinsic Value (USD)  
                               
Outstanding – January 1, 2021     929,765     $ 1.53     $ 2.50                  
Expired forfeited, or cancelled     (560,404 )   $ 1.65     $ 1.66                  
Outstanding – December 31, 2020     369,361     $ 1.35     $ 3.80       5.2     $ 636,156  
                                         
Exercisable at December 31, 2020     369,361     $ 1.35     $ 3.80       5.2     $ 636,156
    Number of Shares     Weighted Average Exercise Price (USD)     Weighted Average Grant Date Fair Value (USD)     Weighted Average Remaining Contractual Term (years)     Aggregate Intrinsic Value (USD)  
                               
Outstanding – January 1, 2019     689,832     $ 1.94     $ 1.94                  
Granted     448,713     $ 1.99     $ 1.49                  
Expired, forfeited, or cancelled     (341,172 )   $ 1.99     $ 0.36                  
Outstanding – December 31, 2019     797,373     $ 1.99     $ 0.72                  
Granted     378,800     $ 0.94     $ 5.22                  
Expired forfeited, or cancelled     (246,408 )   $ 1.94     $ 0.88                  
Outstanding – December 31, 2020     929,765     $ 1.53     $ 2.50       6.1     $ 2,537,245  
                                         
Exercisable at December 31, 2020     929,765     $ 1.53     $ 2.50       6.1     $ 2,537,245  
Schedule of Fair Value Assumption of Stock Option  

The Company utilized the Black-Scholes option-pricing model to determine the fair value of these stock options, using the assumptions as outlined below.

 

Stock Price   $ 5.92  
Dividend Yield     0 %
Expected Volatility     84.7 %
Weighted Average Risk-Free Interest Rate     0.37 %
Expected life (in years)     1.5 – 4.2  

Schedule of Warrants

The following table summarizes information about shares issuable under warrants outstanding at March 31, 2021:

 

    Warrant
shares
outstanding
    Weighted
average
exercise price (USD)
    Weighted average remaining life     Intrinsic value  
Outstanding at January 1, 2021     3,661,178     $ 1.98                  
Issued     3,535,519     $ 4.93                  
Exercised     (851,099 )   $ 4.17                  
Outstanding at March 31, 2021     6,345,598     $ 3.33       4.9     $ 6,049,152  
                                 
Exercisable at March 31, 2021     6,345,598     $ 3.33       4.9     $ 6,049,152  

The following table summarizes information about shares issuable under warrants outstanding at December 31, 2020:

 

    Warrant
shares
outstanding
    Weighted
average
exercise price (USD)
    Weighted average remaining life     Intrinsic value  
Outstanding at January 1, 2019     219,510     $ 2.95       0.08          
Issued     84,381     $ 3.21                  
Outstanding at December 31, 2019     303,891     $ 3.02       1.06     $ -  
Issued     3,222,331     $ 1.96                  
Forfeited     (274,816 )   $ (3.00 )                
Outstanding at December 31, 2020     3,251,406     $ 1.95       4.97     $ -  
                                 
Exercisable at December 31, 2020     3,251,406     $ 1.95       4.97     $ 8,040,545  
Restricted Stock Awards [Member]    
Schedule of Restricted Stock Units and Awards Activity

The Company’s activity in restricted common stock was as follows for the three months ended March 31, 2021:

 

   

Number of

shares

    Weighted
average
grant date
fair
value
 
Non–vested at January 1, 2021     -     $ -  
Granted     70,986     $ 4.16  
Vested     (44,390 )   $ 4.49  
Non–vested at March 31, 2021     26,596     $ 3.61  

 
Restricted Stock Units [Member]    
Schedule of Restricted Stock Units and Awards Activity

The Company’s activity in restricted stock units was as follows for the three months ended March 31, 2021:

 

    Number of shares     Weighted average
grant date fair
value
 
Non–vested at January 1, 2021     -     $ -  
Granted     3,279,284     $ 4.41  
Vested     (1,207,825 )   $ 4.46  
Non–vested at March 31, 2021     2,071,459     $ 4.38